LFM
EW icon

LGT Fund Management’s Edwards Lifesciences EW Stock Holding History

LGT Fund Management’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-3,500
Closed -$268K – 134
2023
Q4 		$268K Buy
+3,500
New +$244K 0.12% 103
2023
Q2 		– Sell
-3,650
Closed -$302K – 130
2023
Q1 		$302K Hold
3,650
– – 0.13% 107
2022
Q4 		$272K Buy
3,650
+272
+8% +$21K 0.12% 104
2022
Q3 		$279K Hold
3,378
– – 0.13% 100
2022
Q2 		$321K Hold
3,378
– – 0.05% 150
2022
Q1 		$416K Hold
3,378
– – 0.06% 152
2021
Q4 		$438K Buy
+3,378
New +$394K 0.13% 101

Other funds holding EW

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

LGT Fund Management's EW Position: Q1 2024 in Review

LGT Fund Management sold out of Edwards Lifesciences (EW) in Q1 2024, closing a stake of 3,500 shares — an estimated $268K sold.

LGT Fund Management first reported a position in EW in Q4 2021 and held it in 7 quarters. The position peaked at $438K in Q4 2021. 1,279 funds tracked by Wall St. Rank hold EW as of Q1 2024.

  • LGT Fund Management reported no remaining Edwards Lifesciences position as of Q1 2024 after selling out during the quarter.
  • LGT Fund Management sold 3,500 Edwards Lifesciences shares in Q1 2024, an estimated $268K.
  • LGT Fund Management first reported a position in Edwards Lifesciences in Q4 2021 and held it in 7 quarters.
  • LGT Fund Management's Edwards Lifesciences position peaked at $438K in Q4 2021.
  • 1,279 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2024.

Based on LGT Fund Management's 13F filing for Q1 2024, filed 14 May 2024.